Review
Copyright ©The Author(s) 2023.
World J Diabetes. Apr 15, 2023; 14(4): 396-411
Published online Apr 15, 2023. doi: 10.4239/wjd.v14.i4.396
Table 1 The benefits of different glucagon-like peptide-1 agonist molecules in the management of diabesity based on recent landmark clinical trials[103]
Drug molecule
Mean weight reduction in kg (95%CI)
Mean % HbA1c reduction (95%CI)
Follow-up period (yr)
Exenatide (weekly)-1.27 (-1.4 to -1.13)-0.53 (-0.57 to -0.50)3.2
Liraglutide-2.3 (-2.5 to -2.0)-0.40 (-0.45 to -0.34)3.8
Lixisenatide-0.7 (-0.9 to -0.5)-0.27 (-0.31 to -0.22)2.1
Albiglutide-0.83 (-1.06 to -0.60)-0.52 (-0.58 to -0.45)1.5
Dulaglutide-1.46 (-1.67 to -1.25)-0.61 (-0.65 to -0.58)5.4
Semaglutide-2.87 (-3.47 to –2.28) for 0.5 mg-0.66 (-0.80 to – 0.52) for 0.5 mg2.0
-4.5 (-4.94 to -3.75) for 1 mg-1.05 (-1.19 to -0.91) for 1 mg
Table 2 The beneficial effects of different sodium glucose cotransporter-2 inhibitors in the management of diabesity based on recent landmark clinical trials[104-108]
Ref.
Drug molecule
Mean weight reduction in kg (SE/95%CI)
Mean % haemoglobin reduction (95%CI)
Follow-up
Neal et al[104], 2017 (CANVAS)Canagliflozin-1.60 (- 1.70 to -1.51)-0.58 (-0.61 to -0.56)3.5 yr
Wiviott et al[105], 2019 (DECLARE)Dapagliflozin-1.80 (-2.00 to -1.70)-0.42 (-0.45 to -0.40)4.2 yr
Häring et al[106], 2014 (EMPA-REG)Empagliflozin-1.63 (-2.11 to -1.5) for 10 mg-0.57 (-0.70 to -0.43) for 10 mg24 wk
-2.01 (-2.49 to -1.53) for 25 mg-0.64 (-0.77 to -0.50) for 25 mg
Rosenstock et al[107], 2018 (VERTIS-MET)Ertugliflozin-3.00 (-3.30 to -2.70) for 5 mg-0.70 (-0.90 to -0.50) for 5 mg24 wk
-2.90 (-3.20 to -2.60) for 15 mg-0.90 (-1.00 to -0.70) for 15 mg
Dagogo-Jack et al[108], 2018 (VERTIS-SITA)Ertugliflozin-2.0 (-2.7 to -1.4) for 5 mg-0.70 (-0.90 to -0.50) for 5 mg26 wk
-1.7 (-2.4 to -1.1) for 10 mg-0.80 (-0.90 to -0.60) for 10 mg